Editorial: Funding, Conflicts, and Paradigms
J Clin Psychiatry 2005;66(5):554
© Copyright 2015 Physicians Postgraduate Press, Inc.
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
This past February and March, the New York Times published an article (Gardiner
Harris and Alex Berenson, “10 Voters on Panel Backing Pain Pills Had Industry Ties,”
Feb 25, 2005) and subsequent editorial (March 4) concerning an FDA Advisory Panel that
recommended marketing of several COX-2 inhibitor analgesics. They cited the Center for
Science in the Public Interest, an advocacy group, which found that 10 of the 37 panel members
had consulted for or received research support from manufacturers of the drugs being
reviewed. The Times then observed that, had the votes of the 10 scientists with industry connections
been excluded, the panel would have voted to withdraw one of the drugs and recommended
blocking the return of another.